Cord Blood Registry and China Cord Blood Corporation Enter into Strategic Collaboration Cord Blood Registry® and China Cord Blood Corporation China’s first and largest umbilical cord blood bank, entered into a memorandum of understanding regarding their strategic collaboration in China and the United States. [Cord Blood Registry®] Press Release Cynata Partners with UWA Centre for Cell Therapy and Regenerative Medicine Cynata Therapeutics Ltd. announced that it has commenced a study to test the potential therapeutic efficacy of its Cymerus™ mesenchymal stem cells in an animal model of lung fibrosis. [Cynata Therapeutics Ltd.] Press Release Valeant Enters into Amended Agreement to Remain Lead Bidder in Acquisition of Dendreon and Its Leading Immunotherapy Treatment, PROVENGE® (Sipuleucel-T) Valeant Pharmaceuticals International, Inc. announced that it entered into an amended and restated “stalking horse” asset purchase agreement to acquire the world-wide rights to Dendreon’s PROVENGE® product and certain other assets of Dendreon Corporation. [Valeant Pharmaceuticals International, Inc.] Press Release Cellular Biomedicine Group (CBMG) Acquiring Chinese PLA General Hospital’s CAR-T (CD19/CD20/CD30/EGFR) Immuno-Oncology Technology and Clinical Data CBMG announced its acquisition of Chinese PLA General Hospital’s chimeric antigen receptor T cell (CAR-T) therapy, its recombinant expression vector CD19, CD20, CD30 and human epidermal growth factor receptor’s immuno-oncology patents, and Phase I/II clinical data of the aforementioned therapies and manufacturing knowledge. [Cellular Biomedicine Group Inc.] Press Release Dicerna Pharmaceuticals Announces First Patient Dosed in Phase Ib/II Clinical Trial of DCR-MYC, an Investigational RNAi Therapeutic Targeting the MYC Oncogene, in Patients with Advanced Hepatocellular Carcinoma Dicerna Pharmaceuticals, Inc. announced that the first patient has been dosed in a global Phase Ib/II clinical trial of DCR-MYC, an investigational Dicer substrate short interfering RNA therapeutic, in patients with advanced hepatocellular carcinoma. [Dicerna Pharmaceuticals, Inc.] Press Release Juno Therapeutics Establishes Manufacturing Presence in Washington State Juno Therapeutics, Inc. announced that it has entered into a lease agreement for a facility in Bothell, Washington to manufacture the company’s cell therapy products. The facility will support Juno’s planned JCAR015 multicenter clinical trial, additional clinical programs in Juno’s pipeline, and the company’s first commercial products. [Juno Therapeutics, Inc.] Press Release Cellular Dynamics Manufactures cGMP HLA “Superdonor” Stem Cell Lines to Enable Cell Therapy with Genetic Matching Cellular Dynamics International, Inc. announced that it has manufactured, under current Good Manufacturing Practices (cGMP), stem cell lines from two HLA (human leukocyte antigens) “superdonors.” [Cellular Dynamics International, Inc.] Press Release Cord Blood Registry Announces Formation of Scientific & Medical Advisory Board Cord Blood Registry® (CBR®) announced the establishment of a Scientific and Medical Advisory Board (SMAB). Composed of internationally renowned stem cell experts, the SMAB will provide input and guidance to help advance CBR’s mission to expand the scope of newborn stem cell therapies that may be available to patients and their families. [Cord Blood Registry®] Press Release |